首页> 外文期刊>The lancet oncology >Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
【24h】

Denosumab: a breakthrough in treatment of giant-cell tumour of bone?

机译:地诺单抗:骨巨细胞瘤治疗的突破?

获取原文
获取原文并翻译 | 示例
           

摘要

Giant-cell tumour (GCT) of bone is a rare primary bone tumour usually occurring in the long bones of young adults. The mechanisms of development of GCT of bone are not well understood and its biological behaviour is unpredictable. GCT of bone is typically benign and intralesional surgical resection is the treatment of choice. If done thoroughly, the patient may be cured in up to 90% of cases.1 But there are some cases of atypical GCT of bone; these might be tumours with multiple local recurrences, multicentricity, pulmonary metastases, or lesions that are impossible to remove surgically without causing substantial morbidity. Although there are reports of beneficial effects of bisphosphonates, to our knowledge, there are no successful prospective trials assessing a systemic therapy.
机译:骨骼的巨细胞瘤(GCT)是一种罕见的原发性骨肿瘤,通常发生在年轻人的长骨中。骨骼的GCT的发展机理还不很清楚,其生物学行为是不可预测的。骨的GCT通常是良性的,病灶内手术切除是首选治疗方法。如果彻底完成,则最多可以治愈90%的病例。1但也有一些非典型的GCT骨病例。这些可能是具有多个局部复发,多中心性,肺转移或无法通过手术切除而不会引起实质性发病的病变的肿瘤。尽管有报道称双膦酸盐具有有益作用,但据我们所知,尚无成功的前瞻性试验评估全身治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号